Christopher Travers, MD
Orthopaedic Surgery · Philadelphia, PANPI 1588923940
Payments from drug & device makers
Across 113 payments — averaging $683.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medical Device Business Services, Inc.$71K
- Stryker$3K
- Zimmer Biomet$2K
- Johnson & Johnson$365
- Heraeus Medical, LLC.$201
- Convatec Inc.$184
- plus $393 from 7 others
What the payments were for
- Consulting fees$2,70027%
- Travel & lodging$3,86639%
- Food & beverage$3,35734%
- Education$210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medical Device Business Services, Inc. | 45 | $70,926 |
| Stryker | 25 | $3,331 |
| Zimmer Biomet | 11 | $1,876 |
| Johnson & Johnson | 10 | $365 |
| Heraeus Medical, LLC. | 11 | $201 |
| Convatec Inc. | 2 | $184 |
| Intellijoint Surgical Inc. | 1 | $146 |
| Baxter Healthcare | 2 | $65 |
| Smith+Nephew | 2 | $62 |
| Biocomposites Inc | 1 | $51 |
| Exactech, Inc. | 1 | $40 |
| KCI USA, Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACTIS$2,700
- MAKO$2,360
- Biowick$1,444
- CORAIL$666
- T2$175
- AQUACEL Ag Extra$169
- ACCOLADE$149
- Intellijoint HIP$146
- ATTUNE$125
- Kincise Surgical Automated System$125
- NexGen$123
How this compares
$77,276 in reported general payments places this provider in the 85th percentile of 1,048 orthopaedic surgery providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Celecoxib | 60 | $1,701 |
| Meloxicam | 104 | $236 |
| Mupirocin | 17 | $159 |
| Naproxen | 12 | $101 |
| Amoxicillin | 38 | $61 |
Paid to pharmacies, not to this prescriber.
Other orthopaedic surgery in Philadelphia
- John FenlinPhiladelphia$5.9M
- Alexander VaccaroPhiladelphia$4.5M
- Joseph AbboudPhiladelphia$4.1M
- Samir MehtaPhiladelphia$3.7M
- Surena NamdariPhiladelphia$1.8M
- Craig IsraelitePhiladelphia$938K
- Andrew KuntzPhiladelphia$732K
- Neil ShethPhiladelphia$633K
- Vahid EntezariPhiladelphia$487K
- Amrit KhalsaPhiladelphia$475K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.